Refocusing of R&D efforts and acceleration of preclinical and clinical programs internationally
Cash of €26.9 million as of June 30, 2022
Financial visibility assured until the 2nd quarter of 2023
Dr. Shefali Agarwal, Chairman and Chief Executive Officer of Onxeo, declares: “This first semester has been the occasion of profound transformations for Onxeo, both in its organization and in its governance, aimed at refocusing our clinical research efforts and strengthening our global presence. This new direction was made possible in particular thanks to the support of our historic shareholders Invus and Financière de la Montagne, who participated in our latest capital increase to secure our operations until the 2nd quarter of 2023.”
To receive all of ONXEO’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.